Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde

Patent metadata

Field	Value
Publication number	US-10077249-B2
Application number	US-201715593198-A
Country	US
Kind code	B2
Filing date	May 11, 2017
Priority date	May 12, 2016
Publication date	Sep 18, 2018
Grant date	Sep 18, 2018

Abstract

Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.

First claim

What is claimed is:

1. A process of synthesizing Compound (I):

the process comprising:
Step (i): treating a compound of formula (2):

wherein each R is independently —CH(CH 2 R 1 )—OR 2 or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl; and wherein each R 1 is independently hydrogen or alkyl, and each R 2 is independently alkyl;
with an acid to provide compound (1):

Step (ii): reacting compound (1) with a compound of formula (3):

wherein LG is a leaving group under alkylation reacting conditions to provide Compound (I); and optionally
Step (iii): crystallizing Compound (I) from Step (ii) from heptane and methyl tert-butyl ether at 45° C. +/−5° C. to 55° C. +/−5° C.

2. The process of claim 1 further comprising formylating a compound of formula (4):

to provide the compound of formula (2):

wherein each
R in compound of formulae (2) and (4) is —CH(CH 2 R 1 )—OR 2 or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl;
R 1 is hydrogen or alkyl, and
R 2 is alkyl.

3. The process of claim 2 further comprising reacting compound (5):

with a vinyl ether of formula CHR 1 ═CHOR 2 (wherein R 1 is hydrogen or alkyl and R 2 is alkyl), or 3,4-dihydro-2H-pyran optionally substituted with one, two or three alkyl, in the presence of a weak acid to provide the compound of formula (4):

wherein each R is —CH(CH 2 R 1 )—OR 2 (where is hydrogen or alkyl and R 2 is alkyl) or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl.

4. The process of claim 3 wherein compound (4) is treated in situ with a formylating agent to provide compound (2).

5. The process of claim 4 wherein compound (2) is treated in situ with an acid to provide compound (1).

6. The process of claim 1 wherein Compound (I) is crystallized from heptane and methyl tert-butyl ether at 45° C. +/−5° C. to 55° C. +/−5° C. to give Compound (I) in substantially pure Form II characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 13.37°, 14.37°, 19.95° or 23.92° 2θ (each ±0.2° 2θ).

7. The process of claim 4 wherein Compound (I) is crystallized from heptane and methyl tert-butyl ether at 45° C. +/−5° C. to 55° C. +/−5° C. to give Compound (I) in substantially pure Form II characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 13.37°, 14.37°, 19.95° or 23.92° 2θ (each ±0.2° 2θ).

8. The process of claim 5 wherein Compound (I) is crystallized from heptane and methyl tert-butyl ether at 45° C. +/−5° C. to 55° C. +/−5° C. to give Compound (I) in substantially pure Form II characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 13.37°, 14.37°, 19.95° or 23.92° 2θ (each ±0.2° 2θ).

9. The process of claim 6 wherein Compound (I) is crystallized at 45° C. to 55° C. to give Compound (I) wherein at least 95% by weight of Compound (I) is Form II.

10. The process of claim 7 wherein Compound (I) is crystallized at 45° C. to 55° C. to give Compound (I) wherein at least 95% by weight of Compound (I) is Form II.

11. The process of claim 8 wherein Compound (I) is crystallized at 45° C. to 55° C. to give Compound (I) wherein at least 95% by weight of Compound (I) is Form II.

12. The process of claim 1 wherein R is —CH(CH 3 )—O—CH 2 CH 3 and the acid for removal of the R groups is an inorganic acid.

13. The process of claim 1 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

14. The process of claim 3 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

15. The process of claim 4 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

16. The process of claim 5 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

17. The process of claim 6 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

18. The process of claim 7 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

19. The process of claim 8 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

20. The process of claim 9 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

21. The process of claim 10 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

22. The process of claim 11 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

23. The process of claim 1 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

24. The process of claim 4 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give subst

Assignees

• Global Blood Therapeutics Inc

Inventors

• Li Zhe
• Guz Nathan
• Shao Yiyang
• Cocuz Julieana
• Frieser Markus
• Yiannikouros George Petros
• Liao Liang

Classifications

• C07D401/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07C45/65

  by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups · CPC title

• C07C47/575 Primary

  containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• C07C47/56 Primary

  containing hydroxy groups · CPC title